OBJECTIVE: The neural basis for autistic spectrum disorders is unclear, but abnormalities in the development of limbic areas and of glutamate have been suggested. Proton magnetic resonance spectroscopy ((1)H-MRS) can be used to measure the concentration of brain metabolites. However, the concentration of glutamate/glutamine in brain regions implicated in autistic spectrum disorders has not yet been examined in vivo. METHOD: The authors used (1)H-MRS to investigate the neuronal integrity of the amygdala-hippocampal complex and a parietal control region in adults with autistic spectrum disorders and healthy subjects. RESULTS: People with autistic spectrum disorders had a significantly higher concentration of glutamate/glutamine and creatine/phosphocreatine in the amygdala-hippocampal region but not in the parietal region. CONCLUSIONS: Abnormalities in glutamate/glutamine may partially underpin the pathophysiology of autistic spectrum disorders, and the authors confirm earlier reports that limbic areas are metabolically aberrant in these disorders.
OBJECTIVE: The neural basis for autistic spectrum disorders is unclear, but abnormalities in the development of limbic areas and of glutamate have been suggested. Proton magnetic resonance spectroscopy ((1)H-MRS) can be used to measure the concentration of brain metabolites. However, the concentration of glutamate/glutamine in brain regions implicated in autistic spectrum disorders has not yet been examined in vivo. METHOD: The authors used (1)H-MRS to investigate the neuronal integrity of the amygdala-hippocampal complex and a parietal control region in adults with autistic spectrum disorders and healthy subjects. RESULTS: People with autistic spectrum disorders had a significantly higher concentration of glutamate/glutamine and creatine/phosphocreatine in the amygdala-hippocampal region but not in the parietal region. CONCLUSIONS: Abnormalities in glutamate/glutamine may partially underpin the pathophysiology of autistic spectrum disorders, and the authors confirm earlier reports that limbic areas are metabolically aberrant in these disorders.
Authors: J L Allen; G Oberdorster; K Morris-Schaffer; C Wong; C Klocke; M Sobolewski; K Conrad; M Mayer-Proschel; D A Cory-Slechta Journal: Neurotoxicology Date: 2015-12-22 Impact factor: 4.294
Authors: Silvia Bernardi; Evdokia Anagnostou; Jun Shen; Alexander Kolevzon; Joseph D Buxbaum; Eric Hollander; Patrick R Hof; Jin Fan Journal: Brain Res Date: 2010-12-23 Impact factor: 3.252
Authors: Tamar Kolodny; Michael-Paul Schallmo; Jennifer Gerdts; Richard A E Edden; Raphael A Bernier; Scott O Murray Journal: Autism Res Date: 2020-04-16 Impact factor: 5.216
Authors: Natalia M Kleinhans; Todd Richards; Kurt E Weaver; Olivia Liang; Geraldine Dawson; Elizabeth Aylward Journal: J Autism Dev Disord Date: 2009-02-21
Authors: David M Cochran; Elif M Sikoglu; Steven M Hodge; Richard A E Edden; Ann Foley; David N Kennedy; Constance M Moore; Jean A Frazier Journal: J Child Adolesc Psychopharmacol Date: 2015-04-28 Impact factor: 2.576